In an exploratory analysis of a clinical trial comparing cabozantinib and everolimus, a different kinase inhibitor, for the treatment of advanced ccRCC, low baseline plasma levels of VEGF and IL-8 were prognostic for better overall survival among patients receiving cabozantinib [45]. The gene discussed is CXCL8; the disease is nonpapillary renal cell carcinoma.